ATE352564T1 - Spheron-komponenten für die bestimmung von verbindungen, die symptome der alzheimer krankheit behandeln können, ihre behandlungen und tiermodelle - Google Patents

Spheron-komponenten für die bestimmung von verbindungen, die symptome der alzheimer krankheit behandeln können, ihre behandlungen und tiermodelle

Info

Publication number
ATE352564T1
ATE352564T1 AT03706165T AT03706165T ATE352564T1 AT E352564 T1 ATE352564 T1 AT E352564T1 AT 03706165 T AT03706165 T AT 03706165T AT 03706165 T AT03706165 T AT 03706165T AT E352564 T1 ATE352564 T1 AT E352564T1
Authority
AT
Austria
Prior art keywords
alzheimer
disease
compounds
treatments
determination
Prior art date
Application number
AT03706165T
Other languages
English (en)
Inventor
Paul Averback
Original Assignee
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp filed Critical Nymox Corp
Application granted granted Critical
Publication of ATE352564T1 publication Critical patent/ATE352564T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03706165T 2002-03-04 2003-03-04 Spheron-komponenten für die bestimmung von verbindungen, die symptome der alzheimer krankheit behandeln können, ihre behandlungen und tiermodelle ATE352564T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36130202P 2002-03-04 2002-03-04

Publications (1)

Publication Number Publication Date
ATE352564T1 true ATE352564T1 (de) 2007-02-15

Family

ID=27789108

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03706165T ATE352564T1 (de) 2002-03-04 2003-03-04 Spheron-komponenten für die bestimmung von verbindungen, die symptome der alzheimer krankheit behandeln können, ihre behandlungen und tiermodelle

Country Status (9)

Country Link
US (1) US20040002460A1 (de)
EP (1) EP1481007B1 (de)
JP (1) JP2005535565A (de)
AT (1) ATE352564T1 (de)
AU (1) AU2003208212A1 (de)
CA (1) CA2478636A1 (de)
DE (1) DE60311433D1 (de)
NZ (1) NZ535275A (de)
WO (1) WO2003074558A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514407B2 (en) * 2002-03-04 2009-04-07 Nymox Corporation Spheron component peptides and pharmaceutical compositions
DE112004001216D2 (de) * 2003-04-25 2006-03-30 Biovision Ag Verfahren zum Nachweis einer neurologischen, demenziellen Erkrankung, die mit einer Verschlechterung des Kurs- oder Langzeitgedächtnis einhergeht, zugehörige proSAAS-Peptide und Nachweisreagenzien
PE20050941A1 (es) 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
US8515882B2 (en) 2010-11-18 2013-08-20 International Business Machines Corporation Efficient storage of individuals for optimization simulation
US8489526B2 (en) 2010-11-24 2013-07-16 International Business Machines Corporation Controlling quarantining and biasing in cataclysms for optimization simulations
US9563844B2 (en) 2011-06-30 2017-02-07 International Business Machines Corporation Speculative asynchronous sub-population evolutionary computing utilizing a termination speculation threshold
US9165247B2 (en) 2012-01-04 2015-10-20 International Business Machines Corporation Using global and local catastrophes across sub-populations in parallel evolutionary computing
US9305257B2 (en) 2013-05-20 2016-04-05 International Business Machines Corporation Adaptive cataclysms in genetic algorithms
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (de) 2020-05-26 2024-11-13 TrueBinding, Inc. Verfahren zur behandlung von entzündungskrankheiten durch galectin-3-blockierung

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5231170A (en) * 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5525339A (en) * 1986-08-27 1996-06-11 Dms Pharmaceutical Inc. Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2251724A1 (en) * 1996-04-15 1997-10-23 Paul Averback Compositions containing bacteriophages and methods of using bacteriophages to treat infections
US6413940B1 (en) * 1997-02-07 2002-07-02 Nymox Corporation Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS
US6130221A (en) * 1997-03-05 2000-10-10 Nymox Corporation Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions
AU3671199A (en) * 1998-04-30 1999-11-16 Regents Of The University Of California, The Host defense enhancement
GB9911802D0 (en) * 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination

Also Published As

Publication number Publication date
WO2003074558A2 (en) 2003-09-12
DE60311433D1 (de) 2007-03-15
AU2003208212A1 (en) 2003-09-16
NZ535275A (en) 2007-03-30
US20040002460A1 (en) 2004-01-01
CA2478636A1 (en) 2003-09-12
EP1481007B1 (de) 2007-01-24
WO2003074558A3 (en) 2003-12-18
JP2005535565A (ja) 2005-11-24
EP1481007A2 (de) 2004-12-01

Similar Documents

Publication Publication Date Title
ATE352564T1 (de) Spheron-komponenten für die bestimmung von verbindungen, die symptome der alzheimer krankheit behandeln können, ihre behandlungen und tiermodelle
DE69926254D1 (de) Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden
EA200100803A2 (ru) Способ имитации общественной реакции на стимулирующее воздействие
WO2005058961A3 (en) Antibodies specific for human galanin, and uses thereof
ATE297755T1 (de) Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
GB0100119D0 (en) Materials and methods relating to protein aggregation in neurodegenerative disease
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
EA200800879A1 (ru) Агонисты ppar гамма для улучшения когнитивной функции у apoe4 отрицательных пациентов
ATE404118T1 (de) System für kontinuierliche leistungstests
ATE545658T1 (de) Verfahren zur behandlung von synovialsarkom
ATE541923T1 (de) Transgener c. elegans als modellorganismus für untersuchungen zur alzheimer'schen krankheit
EP1254260A4 (de) Methoden zur diagnose und behandlung von herzkrankheiten
DE602004026683D1 (de) Verfahren zur diagnose und überwachung von neurologischen erkrankungen durch nachweis eines encephalotoxins
DE69619187D1 (de) Verfahren zur behandlung von motorischen defiziten
ATE373014T1 (de) Einen nanofiltrationsschritt umfassendes verfahren zur aufreinigung von albumin, lösung und zusammensetzung zur therapeutischen anwendung,die dieses enthalten
ATE449964T1 (de) DIAGNOSTISCHE VERWENDUNG VON ßENSADIN-0477ß FÜR NEURODEGENERATIVE ERKRANKUNGEN
ATE316153T1 (de) Diagnose des persönlichen risikos zur entwicklung von diabetischer retinopathie
DE60318065D1 (de) Fcyriia-transgenes tiermodell für autoimmunkrankheit
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
EP1363528A4 (de) Verfahren zur diagnose und behandlung von herzerkrankungen
DE60321355D1 (de) Verfahren zur reproduzierung von pleuromutilinen
ATE380551T1 (de) Verwendung von brimonidine zur behandlung von dementia und morbus parkinson
DK1292187T3 (da) Transgen dyremodel for neurodegenerative lidelser
ATE401576T1 (de) Verwendung eines zum kern beschränkten protein für die diagnose und therapie von alzheimer- krankheit und relatierte neurodegeneratiefe störungen
ATE396200T1 (de) Reagenzien zur diagnose und behandlung von latexallergie und verfahren zu ihrer herstellung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties